(PharmaNewsWire.Com, November 20, 2017 ) North America hemostats market is projected to reach USD 2,608.4 million by 2024, from USD 1,575.2 million in 2016 growing at a CAGR of 6.5% in the forecast period 2017 to 2024.
Based on geography, the North America hemostats market is segmented into 3 geographical regions, such as, U.S., Mexico, Canada,
North America hemostats market competition by top players including- Ethicon US LLC (U.S.) is dominating the hemostats market followed by Pfizer and C.R. Bard Inc., along with others such as Baxter, Vascular Solutions, Inc., B.Braun Melsungen, 3-D Matrix, Ltd.,
Resorba Medical GmbH (an Advanced Medical Solutions Group plc Company), Anika Therapeutics, Inc., Arch Therapeutics Inc., Biom'Up SAS, CryoLife, Inc., Gamma Therapeutics, Inc., Hemostasis, LLC, MedTrade Products Limited, I Integra LifeSciences Corporation, Medline Industries, Inc., HEMOTEC MEDICAL GMBH, Stryker, CSL Behring, Mallinckrodt, Equimedical, B.V.
The North America hemostats market is segmented on the basis of type, application, distribution channel, and end user.
The North America hemostats market is segmented into 5 major types, namely thrombin based hemostats, combination agents, oxidized regenerated cellulose based haemostats, gelatin based haemostats and collagen based haemostats.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
